Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1

Edward P. Acosta, Henry H Balfour

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


To explore a novel method to use nucleosides in heavily treated patients, 4-week cycles of high-dosage (280 mg/d) stavudine were given to 11 asymptomatic patients who had previously received an average of 6 years of nucleoside reverse transcriptase inhibitors (NRTIs). The stavudine dose was targeted to produce a calculated steady-state concentration of 1.5 μM (336 ng/mL). Participants received stavudine for the first 4 weeks, after which it was discontinued for 4 weeks. Additional 4-week drug cycles were given if plasma HIV-1 RNA levels increased to at least 75% of baseline values. The 11 subjects received 38 cycles (average, 3.5 cycles per subject) during the 44-week study. Stavudine was well tolerated. Considering all data, there was a median 0.65 log10 reduction in viral load as well as a median increase in CD4 cell count of 110/mm3 at the end of the cycles. However, plasma viremia increased and CD4 cell counts decreased between cycles. Viral load and CD4 cell responses were similar for up to 4 successive cycles. This suggested that increasing viral resistance was not a problem, as reflected by the acquisition of only one new nucleoside reverse transcriptase mutation among the participants. Significant relationships between stavudine exposure and changes in plasma HIV RNA levels were observed. A similar approach might be considered using a more potent regimen for patients in whom resistance to nucleosides is a major reason for therapeutic failure.

Original languageEnglish (US)
Pages (from-to)343-348
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Issue number3
StatePublished - Jul 1 2003


  • Drug resistance
  • Nucleoside reverse transcriptase inhibitors
  • Pharmacodynamics
  • Stavudine
  • Structured treatment interruption
  • Zidovudine


Dive into the research topics of 'Intermittent administration of high-dose stavudine to nucleoside-experienced individuals infected with HIV-1'. Together they form a unique fingerprint.

Cite this